tetano
Editor, Senior Moderator
Kidney Med
. 2023 Jun;5(6):100627.
doi: 10.1016/j.xkme.2023.100627. Epub 2023 Mar 13. Gross Hematuria Following SARS-CoV-2 Infection in IgA Nephropathy: A Report of 5 Cases
Hiroyuki Ueda[SUP] 1 [/SUP], Masahiro Okabe[SUP] 1 [/SUP], Akihiro Shimizu[SUP] 1 [/SUP], Shinya Yokote[SUP] 1 [/SUP], Akio Nakashima[SUP] 1 [/SUP], Nobuo Tsuboi[SUP] 1 [/SUP], Masato Ikeda[SUP] 1 [/SUP], Yoichi Miyazaki[SUP] 1 [/SUP], Takashi Yokoo[SUP] 1 [/SUP]
Affiliations
Gross hematuria after upper respiratory tract infections is a well-known characteristic symptom of immunoglobulin A nephropathy (IgAN). In recent years, there have been several reports of existing or newly diagnosed patients with IgAN susceptible to gross hematuria after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. However, reports of patients with IgAN and gross hematuria after SARS-CoV-2 infection are extremely rare despite a considerable number of patients with coronavirus disease 2019 (COVID-19) who preferentially present with upper respiratory symptoms. Here, we report the cases of 5 Japanese patients with IgAN who developed gross hematuria associated with SARS-CoV-2 infection. These patients presented with fever and other COVID-19-related symptoms, followed by the appearance of gross hematuria within 2 days, which lasted for 1-7 days. Acute kidney injury occurred after gross hematuria in 1 case. In all cases, microhematuria was identified before gross hematuria associated with SARS-CoV-2 infection, and it persisted after the gross hematuria episode. Because repeated gross hematuria and persistent microhematuria may lead to irreversible kidney injury, the clinical manifestations of patients with IgAN during the COVID-19 pandemic should be carefully monitored.
Keywords: COVID-19; IgA nephropathy; SARS-CoV-2; gross hematuria; kidney.
. 2023 Jun;5(6):100627.
doi: 10.1016/j.xkme.2023.100627. Epub 2023 Mar 13. Gross Hematuria Following SARS-CoV-2 Infection in IgA Nephropathy: A Report of 5 Cases
Hiroyuki Ueda[SUP] 1 [/SUP], Masahiro Okabe[SUP] 1 [/SUP], Akihiro Shimizu[SUP] 1 [/SUP], Shinya Yokote[SUP] 1 [/SUP], Akio Nakashima[SUP] 1 [/SUP], Nobuo Tsuboi[SUP] 1 [/SUP], Masato Ikeda[SUP] 1 [/SUP], Yoichi Miyazaki[SUP] 1 [/SUP], Takashi Yokoo[SUP] 1 [/SUP]
Affiliations
- PMID: 37144236
- PMCID: PMC10056602
- DOI: 10.1016/j.xkme.2023.100627
Gross hematuria after upper respiratory tract infections is a well-known characteristic symptom of immunoglobulin A nephropathy (IgAN). In recent years, there have been several reports of existing or newly diagnosed patients with IgAN susceptible to gross hematuria after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. However, reports of patients with IgAN and gross hematuria after SARS-CoV-2 infection are extremely rare despite a considerable number of patients with coronavirus disease 2019 (COVID-19) who preferentially present with upper respiratory symptoms. Here, we report the cases of 5 Japanese patients with IgAN who developed gross hematuria associated with SARS-CoV-2 infection. These patients presented with fever and other COVID-19-related symptoms, followed by the appearance of gross hematuria within 2 days, which lasted for 1-7 days. Acute kidney injury occurred after gross hematuria in 1 case. In all cases, microhematuria was identified before gross hematuria associated with SARS-CoV-2 infection, and it persisted after the gross hematuria episode. Because repeated gross hematuria and persistent microhematuria may lead to irreversible kidney injury, the clinical manifestations of patients with IgAN during the COVID-19 pandemic should be carefully monitored.
Keywords: COVID-19; IgA nephropathy; SARS-CoV-2; gross hematuria; kidney.